Evidence map›Paper›PMID 41323409›Full record

ArticleTherapeutics and clinical risk management2025

CHA

Xiao Long, Qiao Jin, Luping Jiang, Ran Chen, Lu Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutics and clinical risk management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiao LongDepartment of Cardiovascular Medicine, Changsha Central Hospital, Changsha, People's Republic of China.
Qiao JinDepartment of Cardiovascular Medicine, Changsha Central Hospital, Changsha, People's Republic of China.
Luping JiangDepartment of Cardiovascular Medicine, Changsha Central Hospital, Changsha, People's Republic of China.
Ran ChenDepartment of Cardiovascular Medicine, Changsha Central Hospital, Changsha, People's Republic of China.
Lu HuDepartment of Cardiovascular Medicine, Changsha Central Hospital, Changsha, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate the prognostic value of the CHA Patients and Methods: This retrospective study included 992 consecutive ACS patients without AF who underwent PCI from January 2019 to December 2022. Patients were stratified into low- (0-1), moderate- (2), and high-risk (>2) groups based on the CHA Results: During the 12-month follow-up, MACE occurred in 12.7%, 21.4%, and 28.8% of the low-, moderate-, and high-risk groups, respectively ( Conclusion: The CHA

Indexed as

acute coronary syndromeCHA2DS2-VASc scoremajor adverse cardiovascular eventspercutaneous coronary interventionrisk stratification

Identifiers

PMID41323409
PMCPMC12664308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.